NCT03801369View on ClinicalTrials.gov

Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

October 22, 2024

Study Completion Date

December 23, 2024

Conditions
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma
Interventions
PROCEDURE

Biopsy

Undergo biopsy

DRUG

Capivasertib

Given PO (orally)

DRUG

Ceralasertib

Given PO (orally)

BIOLOGICAL

Durvalumab

Given IV (infusion)

DRUG

Olaparib

Given PO (orally)

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Selumetinib

Given PO (orally)

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Oregon Health and Science University

OTHER

lead

Gordon Mills, MD, PhD

OTHER